CN112028978B - 新冠病毒特异性cd8+t细胞表位肽及其应用 - Google Patents
新冠病毒特异性cd8+t细胞表位肽及其应用 Download PDFInfo
- Publication number
- CN112028978B CN112028978B CN202010929828.0A CN202010929828A CN112028978B CN 112028978 B CN112028978 B CN 112028978B CN 202010929828 A CN202010929828 A CN 202010929828A CN 112028978 B CN112028978 B CN 112028978B
- Authority
- CN
- China
- Prior art keywords
- seq
- peptide
- cell epitope
- hla
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 93
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 40
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 229940022962 COVID-19 vaccine Drugs 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 34
- 102100037850 Interferon gamma Human genes 0.000 abstract description 17
- 108010074328 Interferon-gamma Proteins 0.000 abstract description 17
- 238000011161 development Methods 0.000 abstract description 6
- 229960005486 vaccine Drugs 0.000 abstract description 4
- 206010035664 Pneumonia Diseases 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 28
- 108010075704 HLA-A Antigens Proteins 0.000 description 28
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 20
- 150000001413 amino acids Chemical group 0.000 description 19
- 208000025721 COVID-19 Diseases 0.000 description 13
- 238000012216 screening Methods 0.000 description 11
- 241000700605 Viruses Species 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 8
- 241001678559 COVID-19 virus Species 0.000 description 7
- 101710139375 Corneodesmosin Proteins 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 102100031673 Corneodesmosin Human genes 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241001292005 Nidovirales Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
序号 | pep_ID | 氨基酸序号 | 氨基酸序列 | HLA限制性 | 抗原来源 |
1 | P64 | SEQ ID NO:1 | KTFPPTEPK | A1101 | N |
2 | P63 | SEQ ID NO:2 | KLDDKDPNF | A0201 | N |
3 | P04 | SEQ ID NO:3 | RLDKVEAEV | A0201 | S |
4 | P16 | SEQ ID NO:4 | FTISVTTEI | A0201 | S |
5 | P61 | SEQ ID NO:5 | LLLDRLNQL | A0201 | N |
6 | P62 | SEQ ID NO:6 | GMSRIGMEV | A0201 | N |
7 | P77 | SEQ ID NO:7 | LALLLLDRL | A0201 | N |
8 | P74 | SEQ ID NO:8 | ALNTLVKQL | A0201 | S |
9 | P45 | SEQ ID NO:9 | NYNYLYRLF | A2402 | S |
10 | P49 | SEQ ID NO:10 | EYVSQPFLM | A2402 | S |
11 | P52 | SEQ ID NO:11 | VYDPLQPEL | A2402 | S |
12 | P53 | SEQ ID NO:12 | IYQTSNFRV | A2402 | S |
13 | P54 | SEQ ID NO:13 | VFKNIDGYF | A2402 | S |
14 | P55 | SEQ ID NO:14 | HWFVTQRNF | A2402 | S |
15 | P57 | SEQ ID NO:15 | GYLQPRTFL | A2402 | S |
16 | S-7 | SEQ ID NO:16 | NATRFASVYAWNRKR | 未知 | S |
17 | S-8 | SEQ ID NO:17 | FASVYAWNRKRISNC | 未知 | S |
18 | S-10 | SEQ ID NO:18 | RKRISNCVADYSVLY | 未知 | S |
19 | S-11 | SEQ ID NO:19 | SNCVADYSVLYNSAS | 未知 | S |
20 | S-44 | SEQ ID NO:20 | PLQSYGFQPTNGVGY | 未知 | S |
Claims (2)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310536175.3A CN116375822A (zh) | 2020-09-07 | 2020-09-07 | 新冠病毒特异性cd8+t细胞表位肽及其应用 |
CN202010929828.0A CN112028978B (zh) | 2020-09-07 | 2020-09-07 | 新冠病毒特异性cd8+t细胞表位肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010929828.0A CN112028978B (zh) | 2020-09-07 | 2020-09-07 | 新冠病毒特异性cd8+t细胞表位肽及其应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310536175.3A Division CN116375822A (zh) | 2020-09-07 | 2020-09-07 | 新冠病毒特异性cd8+t细胞表位肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112028978A CN112028978A (zh) | 2020-12-04 |
CN112028978B true CN112028978B (zh) | 2023-06-16 |
Family
ID=73585666
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310536175.3A Pending CN116375822A (zh) | 2020-09-07 | 2020-09-07 | 新冠病毒特异性cd8+t细胞表位肽及其应用 |
CN202010929828.0A Active CN112028978B (zh) | 2020-09-07 | 2020-09-07 | 新冠病毒特异性cd8+t细胞表位肽及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310536175.3A Pending CN116375822A (zh) | 2020-09-07 | 2020-09-07 | 新冠病毒特异性cd8+t细胞表位肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN116375822A (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021198999A1 (en) * | 2020-04-03 | 2021-10-07 | Axon Neuroscience Se | Epitope-based vaccines for treatment of coronavirus associated diseases |
CN111548396B (zh) * | 2020-04-17 | 2021-07-20 | 暨南大学 | 一种新型冠状病毒T细胞抗原表位肽、pMHC及其制备和应用 |
WO2021226520A1 (en) * | 2020-05-08 | 2021-11-11 | Kiromic BioPharma, Inc. | Peptide compositions for the treatment of pathogenic infections |
CN114621329A (zh) * | 2021-05-10 | 2022-06-14 | 半桔生物科技有限公司 | 一种t细胞表位肽复合物 |
CN114591401A (zh) * | 2021-05-18 | 2022-06-07 | 深圳市因诺转化医学研究院 | SARS-CoV-2编码蛋白来源的T细胞表位多肽HLVDFQVTI及其应用 |
WO2022244891A1 (ja) * | 2021-05-21 | 2022-11-24 | 北海道公立大学法人札幌医科大学 | SARS-CoV-2由来のT細胞エピトープペプチド |
CN113633763B (zh) * | 2021-06-28 | 2023-04-28 | 南华大学 | 一种新型冠状病毒s1-e疫苗及其制备方法 |
CN114181320B (zh) * | 2021-12-09 | 2023-04-25 | 新疆医科大学第一附属医院 | 一种针对新冠原始株和变异株的重组多表位疫苗rSMEV及其应用 |
CN115716867B (zh) * | 2022-11-24 | 2023-08-08 | 扬州大学 | 一种V型分泌系统MisL展呈表达新型冠状病毒受体结合域B细胞表位抗原和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111228483A (zh) * | 2020-03-19 | 2020-06-05 | 四川大学 | 用于新型冠状病毒和非典病毒的广谱抗体喷剂 |
CN111978378A (zh) * | 2020-08-10 | 2020-11-24 | 武汉大学 | SARS-CoV-2抗原多肽及其应用 |
US10973909B1 (en) * | 2020-04-03 | 2021-04-13 | Peptc Vaccines Limited | Coronavirus vaccine |
CN113557431A (zh) * | 2020-02-19 | 2021-10-26 | 欧蒙医学实验诊断股份公司 | 诊断SARS-CoV-2感染的方法和试剂 |
-
2020
- 2020-09-07 CN CN202310536175.3A patent/CN116375822A/zh active Pending
- 2020-09-07 CN CN202010929828.0A patent/CN112028978B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113557431A (zh) * | 2020-02-19 | 2021-10-26 | 欧蒙医学实验诊断股份公司 | 诊断SARS-CoV-2感染的方法和试剂 |
CN111228483A (zh) * | 2020-03-19 | 2020-06-05 | 四川大学 | 用于新型冠状病毒和非典病毒的广谱抗体喷剂 |
US10973909B1 (en) * | 2020-04-03 | 2021-04-13 | Peptc Vaccines Limited | Coronavirus vaccine |
CN111978378A (zh) * | 2020-08-10 | 2020-11-24 | 武汉大学 | SARS-CoV-2抗原多肽及其应用 |
Non-Patent Citations (5)
Title |
---|
Cytotoxic T-Lymphocyte Elicited Vaccine against SARS-CoV-2 employing Immunoinformatics Framework;Neeraj Kumar等;《Research Square》;20200709;全文 * |
Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2;LinLi等;《Virus Research》;20200701;全文 * |
Identification and characterization of an immunodominant SARS-CoV-2-specific CD8 T cell response;Anastasia Gangaev等;《Research Square》;20200604;全文 * |
Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants;ChaoHu等;《Genes & Diseases》;20210629;第9卷(第1期);全文 * |
新冠灭活疫苗与蛋白疫苗免疫恒河猴的T细胞受体库的特征分析;左原源;《中国知网》;20211231;全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN112028978A (zh) | 2020-12-04 |
CN116375822A (zh) | 2023-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112028978B (zh) | 新冠病毒特异性cd8+t细胞表位肽及其应用 | |
Oh et al. | Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope | |
CN113735947A (zh) | 新型冠状病毒s蛋白全蛋白组筛选的特异性t细胞表位肽p48及其应用 | |
CN113801208B (zh) | 一种新型冠状病毒的t细胞免疫检测方法 | |
CN105601747A (zh) | 一种结核杆菌融合蛋白及其在诱导外周血单个核细胞产生细胞因子的应用 | |
CN105481947A (zh) | 结核分枝杆菌特异性cd4+t细胞表位肽p12及其应用 | |
CN102212113B (zh) | 结核耐药相关外排蛋白来源抗结核ctl表位肽及其应用 | |
CN116496383A (zh) | 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用 | |
CN104491857B (zh) | 一种用于免疫治疗ebv相关疾病的抗原组合物、生物制剂及其制备方法 | |
CN106405107B (zh) | 结核分枝杆菌抗原蛋白Rv2941及其T细胞表位肽的应用 | |
Six et al. | Antigenic analysis of H1N1 viruses isolated in the Houston metropolitan area during four successive seasons | |
CN114907453B (zh) | 一种用于治疗SARS-CoV-2病毒感染的S蛋白多肽 | |
Plata | Specificity studies on cytolytic T lymphocytes directed against murine leukemia virus-induced tumors. Analysis of monoclonal cytolytic T lymphocytes. | |
CN102731617A (zh) | 汉滩病毒糖蛋白特异性t细胞表位肽及其应用 | |
CN103130873A (zh) | 结核耐药相关外排蛋白来源抗结核ctl表位肽及其应用 | |
CN114949194B (zh) | 一种用于治疗SARS-CoV-2病毒感染的多肽制剂 | |
CN114907452B (zh) | 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽 | |
CN113735946A (zh) | 新型冠状病毒s蛋白全蛋白组筛选的特异性t细胞表位肽p38及其应用 | |
CN106248936B (zh) | 结核分枝杆菌抗原蛋白Rv2201及其T细胞表位肽的应用 | |
CN106248935B (zh) | 结核分枝杆菌抗原蛋白Rv1798及其T细胞表位肽的应用 | |
CN106442983B (zh) | 结核分枝杆菌抗原蛋白Rv3793及其T细胞表位肽的应用 | |
CN104387448B (zh) | 结核分枝杆菌特异性cd8+t细胞表位肽p46及其应用 | |
CN104356198A (zh) | 结核分枝杆菌特异性cd8+t细胞表位肽p16及其应用 | |
CN104327159A (zh) | 结核分枝杆菌特异性cd8+t细胞表位肽p45及其应用 | |
WO2023051611A1 (zh) | SARS-CoV-2特异性多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Shen Meiying Inventor after: Hu Chao Inventor after: Han Xiaojian Inventor after: Jin Aishun Inventor after: Wang Yingming Inventor after: Li Shenglong Inventor after: Chen Qian Inventor before: Jin Aishun Inventor before: Hu Chao Inventor before: Han Xiaojian Inventor before: Shen Meiying Inventor before: Wang Yingming Inventor before: Li Shenglong Inventor before: Chen Qian |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |